Comparative Pharmacology
Head-to-head clinical analysis: ISOPAQUE 280 versus RENOVIST II.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOPAQUE 280 versus RENOVIST II.
ISOPAQUE 280 vs RENOVIST II
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isopaque 280 (metrizoate) is an ionic, high-osmolar iodinated radiocontrast agent that attenuates X-rays by increasing the density of tissues where it distributes, thereby enhancing vascular and organ visualization during imaging.
RENOVIST II is a radiographic contrast agent that contains diatrizoate meglumine and diatrizoate sodium. It increases the radiopacity of vascular structures and organs by attenuating X-rays due to the high atomic number of iodine atoms in the molecule.
Iohexol (ISOPAQUE 280) is administered intravenously, intra-arterially, or by other appropriate routes. Typical adult dose for CT imaging: 50–150 mL (concentration 280 mg I/mL) as a bolus or infusion. For angiography: 5–80 mL per injection, depending on procedure. Repeat doses may be given up to a total of 350 mL.
1-2 mL/kg IV bolus, not to exceed 150 mL total; may be repeated once if necessary.
None Documented
None Documented
Terminal elimination half-life is 1.5–2 hours in patients with normal renal function; prolonged to >10 hours in severe renal impairment, requiring dose adjustment.
1.2 hours in patients with normal renal function; prolonged to 8–12 hours in severe renal impairment (CrCl <30 mL/min).
Renal: approximately 95% of the dose is excreted unchanged in the urine within 24 hours via glomerular filtration. Fecal: <5%; biliary excretion is negligible.
Renal: 95% as unchanged drug via glomerular filtration; fecal: <5%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent